ARI 3037MO

Drug Profile

ARI 3037MO

Alternative Names: ARI-3037MO

Latest Information Update: 16 Aug 2016

Price : $50

At a glance

  • Originator Arisaph Pharmaceuticals
  • Class Antihyperlipidaemics; Small molecules
  • Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyslipidaemias; Hypertriglyceridaemia; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Jun 2016 Arisaph Pharmaceuticals completes phase-II clinical trials in Hypertriglyceridaemia in USA (PO) (NCT02250105)
  • 01 Oct 2015 Arisaph Pharmaceuticals initiates enrolment in a phase II trial for Non-alcoholic steatohepatitis and non-alcoholic fatty liver disease in USA (NCT02574325)
  • 01 Aug 2015 Phase-II clinical trials in Dyslipidaemias in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top